Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis
JAMA Neurol 72:1170-1174, Peeler, C.E.,et al, 2015
Two Cases of Congenital Myasthenic Syndrome with Vocal Cord Paralysis
Neurol 84:1281-1282, Al-Shahoumi, R.,et al, 2015
Differential Diagnosis of Finger Drop
Neurologist 19:128-131, Varatharaj, A.,et al, 2015
Paraneoplastic Neurologic Disorders in Small Cell Lung Carcinoma
Neurol 85:235-239, Gozzard, P.,et al, 2015
Myasthenia in Pregnancy: Best Practice Guidelines from a UK Multispecialty Working Group
JNNP 85:538-543, Norwood, F.,et al, 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Paraneoplastic Neurological Syndromes
Clin Exp Immunol 175:336-348, Leypoldt, F. & Wandinger, K.-P., 2014
Juvenile Myasthenia Gravis: Recommendations for Diagnostic Approaches and Treatment
Neuropediatrics 45:75-83, Marina, A.D.,et al, 2014
Diagnosis of Lambert-Eaton Myasthenic Syndrome in Children
Neurol 80:e220-e222, Morgan-Followell,B.& de los Reyes,E., 2013
Overlooked non-motor Symptoms in Myasthenia Gravis
JNNP 84:989-994, Suzuki, S.,et al, 2013
Clinicopathologic Conference, Inflammatory Myopathy and Myasthenia Gravis Assoc. with Thymoma
NEJM 369:764-773, Case 26-2013, 2013
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Myasthenia Gravis
BMJ 345:e8497, Spillane, J.,et al, 2012
Clinicopathologic Conference, Thymoma with Paraneoplastic Myasthenia Gravis, Polymyositis and Myocarditis, and Brain Stem Encephalitis
NEJM 365:2413-2422, Case 39-2011, 2011
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Use and monitoring of low dose rituximab in myasthenia gravis
JNNP 82:659-663, Blum, S., et al, 2011
Myasthenia Gravis as a Cause of Head Drop in Parkinson Disease
The Neurologist 17:144-146, Uludag, I.F.,et al, 2011
Comparison of IVIg and PLEX in patients with myasthenia gravis
Neurol 76:2017-2023, Barth, D.,et al, 2011
Comparative Analysis of Therapeutic Options Used for Myasthenia Gravis
Ann Neurol 68:797-805, Mandawat,A.,et al, 2010
Redefining Dysferlinopathy Phenotypes Based on Clinical Findings and Muscle Imaging Studies
Neurol 75:316-323,298, Paradas,C., et al, 2010
Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia Gravis
Arch Neurol 66:1334-1338, 1322, Suzuki,S.,et al, 2009
Multifocal Paraneoplastic Cortical Encephalitis Associated With Myasthenia Gravis and Thymoma
Arch Neurol 66:1407-1409, Hammoud,K.,et al, 2009
Incidence and Mortality Rates of Myasthenia Gravis and Myasthenic Crisis in US Hospitals
Neurol 72:1548-1554, Alshekhlee,A.,et al, 2009
Tempo of Disease. In Merritts Neurology. Signs and symptoms in neurologic diagnosis: Approach to the patient
, Rowland, L.P.,et al, 2009
A Case with Myasthenia Gravis, Brain Stem Multiple Infarcts, Fracture of Vertebrai Th6 and discal hernia to the Th7/Th8
Radiol Oncol 43:3:170-174, KuKaj,V.,et al, 2009
Immunosuppressant Drugs for Myasthenia Gravis
JNNP 80:5-6, Hart,I.K.,et al, 2008
A Trial of Mycophenolate Mofetil With Prednisone as Initial Immunotherapy of Myasthenia Gravis
Neurol 71:394-399,390, The Muscle Study Group, 2008
An International, Phase III, Randomized Trial of Mycophenolate Mofetil in Myasthenia Gravis
Neurol 71:400-406, 390, Sanders,D.B.,et al., 2008
Treatment of Ocular Symptoms in Myasthenia Gravis
Neurol 71:1335-1341, Bhanushali,M.J.,et al, 2008
SOX1 Antibodies Are Markers of Paraneoplastic Lambert-Eaton Myasthenic Syndrome
Neurol 70:924-928, Sabater,L.,et al, 2008
Classification of Myasthenia Gravis Based on Autoantibody Status
Arch Neurol 64:1121-1124, Suzuki,S.,et al, 2007
Mysterious Falls and a Nasal Voice
Lancet 370:712, Bhandari,A. &Adenwalla,F., 2007
Immunosuppressive or Surgical Treatment for Ocular Myasthenia Gravis
Arch Neurol 64:1792-1794,1794, Chavis,P.S.,et al, 2007
Ocular Myasthenia Gravis Treatment: The Case Against Prednisone Therapy and Thymectomy
Arch Neurol 64:1790-1792,1794, Gilbert,M.E.,et al, 2007
Bilateral Ocular Paralysis: Analysis of 31 Inpatients
Arch Neurol 64:178-180, Keane,J.R., 2007
IV Immunoglobulin in Patients With Myasthenia Gravis
Neurol 68:837-841,803, Zinman,L., et al, 2007
Evidence Report: The Medical Treatment of Ocular Myasthenia (An Evidence-Based Review)
Neurol 68:2144-2149, Benatar,M. &Kaminski,H.J., 2007
Myasthenia gravis Exacerbation or Unmasking Associated With Telithromycin Treatment
Neurol 67:2256-2258, Perrot,S.,et al, 2006
Extrathymic Tumors in Patients With Myasthenia Gravis, A 35-Year Retrospective Study
The Neurologist 12:53-55, Wakata,N.,et al, 2006
Causes of Death Among Patients with Myasthenia Gravis in Norway Between 1951 and 2001
JNNP 77:203-207, Owe,J.F.,et al, 2006
Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006
Ocular Myasthenia: Diagnosis, Treatment and Pathogenesis
The Neurologist 12:231-239, Kusner,L.,et al, 2006
Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders
Arch Neurol 63:1066-1071, Lehmann,H.C.,et al, 2006
Concomitant Chronic Inflammatory Demyelinating Polyneuropathy and Myasthenia Gravis Following Cytomegalovirus Infection
J Neurol Sci 240:103-106, Mori, M.,et al, 2006
Treatment of Myasthenia Gravis Exacerbation with Intravenous Immunoglobulin
Arch Neurol 62:1689-1693, Gajdos,P.,et al, 2005
Dysphagia as the Sole Manisfestation of Myasthenia Gravis
JNNP 76:1297-1300, Llabrs,M.,et al, 2005
Primary CNS Lymphoma in Myasthenic on Long-term Azathioprine
J NeuroOncol 74:91-92, Finelli,P.F., 2005
Primary CNS Lymphoma Complicating Treatment of Myasthenia Gravis with Mycophenolate Mofetil
Neurol 65:639-641, Vernino,S.,et al, 2005
Lambert-Eaton Myasthenic Syndrome Associated With Thymitis
Neurol 64:168-169, Warren,N.M.,et al, 2005